Mutations in mitochondrial DNA causing tubulointerstitial kidney diseaseReportar como inadecuado


Mutations in mitochondrial DNA causing tubulointerstitial kidney disease


Mutations in mitochondrial DNA causing tubulointerstitial kidney disease - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Publication Date: 2017-03-07

Journal Title: PLoS Genetics

Publisher: PLoS

Volume: 13

Issue: 3

Number: e1006620

Language: English

Type: Article

This Version: VoR

Metadata: Show full item record

Citation: Connor, T., Hoer, S. S., Mallett, A., Gale, D., Gomez Duran, A., Posse, V., Antrobus, R., et al. (2017). Mutations in mitochondrial DNA causing tubulointerstitial kidney disease. PLoS Genetics, 13 (3. e1006620)https://doi.org/10.1371/journal.pgen.1006620

Abstract: Tubulointerstitial kidney disease is an important cause of progressive renal failure whose aetiology is incompletely understood. We analysed a large pedigree with maternally inherited tubulointerstitial kidney disease and identified a homoplasmic substitution in the control region of the mitochondrial genome (m.547A>T). While mutations in mtDNA coding sequence are a well recognised cause of disease affecting multiple organs, mutations in the control region have never been shown to cause disease. Strikingly, our patients did not have classical features of mitochondrial disease. Patient fibroblasts showed reduced levels of mitochondrial tRNA$^{Phe}$, tRNA$^{Leu1}$ and reduced mitochondrial protein translation and respiration. Mitochondrial transfer demonstrated mitochondrial transmission of the defect and in vitro assays showed reduced activity of the heavy strand promoter. We also identified further kindreds with the same phenotype carrying a homoplasmic mutation in mitochondrial tRNA$^{Phe}$ (m.616T>C). Thus mutations in mitochondrial DNA can cause maternally inherited renal disease, likely mediated through reduced function of mitochondrial tRNA$^{Phe}$.

Sponsorship: This study was supported by a Wellcome Trust Senior Investigator Award to PHM [19710], by the National Institute for Health Research Cambridge and Imperial Biomedical Research Centres, and a Medical Research Council Clinical Training Fellowship awarded to TMC. The core facilities at CIMR were funded by a Wellcome Trust strategic award [100140]. PFC is a Wellcome Trust Senior Fellow in Clinical Science [101876/Z/13/Z] within the Medical Research Council Mitochondrial Biology Unit [MC_UP_1501/2]. CMG was supported by The Swedish Medical Research Council and The Knut and Alice Wallenberg Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Embargo Lift Date: 2100-01-01

Identifiers:

External DOI: https://doi.org/10.1371/journal.pgen.1006620

This record's URL: https://www.repository.cam.ac.uk/handle/1810/264385



Rights: Attribution 4.0 International

Licence URL: http://creativecommons.org/licenses/by/4.0/





Autor: Connor, TMHoer, Simon SebastianMallett, AGale, DPGomez Duran, AuroraPosse, VAntrobus, RMoreno, PSciacovelli, Marco Frezza, Christi

Fuente: https://www.repository.cam.ac.uk/handle/1810/264385



DESCARGAR PDF




Documentos relacionados